Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2003-12-05
2010-12-07
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091310, C536S023100, C536S024310, C536S024500
Reexamination Certificate
active
07846730
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided.
REFERENCES:
patent: 5691179 (1997-11-01), Korsmeyer
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5955595 (1999-09-01), Korsmeyer
patent: 6133246 (2000-10-01), McKay et al.
patent: 6140484 (2000-10-01), Bitler et al.
patent: 6500626 (2002-12-01), Korsmeyer
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6821724 (2004-11-01), Mittman et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2007/0031851 (2007-02-01), Velculescu et al.
patent: WO 03/006029 (2002-07-01), None
patent: WO 02/72130 (2002-09-01), None
Zhou et al., J. Biol. Chem., vol. 273, No. 19, pp. 11,930-11,936 (1998).
Apte, S.S. et al., Genomics, vol. 26, pp. 592-594 (1995).
Peracchi, A., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Crooke, S., Antisense Research & Application, Chapter 1, pp. 1-50, Ed. by S. T. Crooke, Publ. by Springer-verlag (1998).
Branch, A.D., Trends in Biochem. Sci. (TIBS), vol. 23, pp. 45-50 (1998).
Milner, N. et al., Bature Biotech., vol. 15, pp. 537-541 (1997).
Chirila, T.V., et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Dibbert, B. et al., Proc. Natl. Acad. Sci., vol. 96, No. 23, pp. 13,330-13,335 (1999).
Manfredini, R. et al., Antisense & Nucleic Acid Drug Dev., vol. 8, pp. 341-350 (1998).
Afford et al., Apoptosis,Mol. Pathol., 2000, 53:55-63.
Apte et al., Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta,Genomics, 1995, 26:592-594.
Brousset et al.,Frequent expression of the cell death-inducing gene Bax Reed-Sternberg cells of Hodgkins's disease,Blood, 1996, 87:2470-2475.
Chou et al., The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas,Cancer Genet. Cytogenet., 1996, 88:136-140.
Dibbert et al., Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mecahnism to accumulate effector cells in inflammation,Proc. Natl. Acad. Sci. U. S. A., 1999, 96:13330-13335.
Gillardon et al., Antisense oligodeoxynucleotides to bax mRNA promote survival of rat sympathetic neurons in culture,J. Neurosci. Res., 1996, 43:726-734.
Isenmann et al., Bax antisense oligonucleotides reduce axotomy-induced-retinal ganglion cell death in vivo by reduction of Bax protein expression,Cell Death Differ., 1999, 6:673-682.
Knudson et al., Bax-deficient mice with lymphoid hyperplasia and male germ cell death,Science, 1995, 270:96-99.
Korsmeyer et al., Death and survival signals determine active/inactive conformations of pro-apoptotic BAX, BAD, and BID molecules,Cold Spring Harb. Symp. Quant. Biol., 1999, 64:343-350.
Korsmeyer et al., Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c,Cell Death Differ., 2000, 7:1166-1173.
MacGibbon et al., Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus,Brain Res., 1997, 750:223-234.
Manfredini et al., Antisense inhibition of Bax mRNA increases survival of terminally differentiated HL60 cells,Antisense Nucleic Acid Drug Dev., 1998, 8:341-350.
Oltvai et al., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death,Cell, 1993, 74:609-619.
Otter et al., The binding properties of biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli,J. Biol. Chem., 1998, 273:6110-6120.
Park et al., Differential expression of Bax and Bcl-2 in the brains of hamsters infected with 263K scrapie agent,NeuroReport, 2000, 11:1677-1682.
Perez et al., Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency,Nat. Genet., 1999, 21:200-203.
Podesta et al., Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro,Am. J. Pathol., 2000, 156:1025-1032.
Shi et al., Identification and characterization of baxepsilon, a novel bax variant missing the BH2 and the transmembrane domains,Biochem. Biophys. Res. Commun., 1999, 254:779-785.
Tamatani et al., Involvement of Bcl-2 family and caspase-3-like protease in NO-mediated neuronal apoptosis,J. Neurochem., 1998, 71:1588-1596.
Tamatani et al., Growth factors prevent changes in Bcl-2 and bax expression and neuronal apoptosis induced by nitric oxide,Cell Death Differ., 1998, 5:911-919.
Vila et al., Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease,Proc. Natl. Acad. Sci. U. S. A., 2001, 98:2837-2842.
Vukosavic et al., Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis,J. Neurochem., 1999, 73:2460-2468.
Yel et al., Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2,J. Clin. Immunol., 1999, 19:428-434.
Yoshimura et al., Expression of bcl-2 and bax in glomerular disease,Nephrol. Dial. Transplant, 1999, 14:55-57.
Zhou et al., A novel splice variant of the cell death-promoting protein BAX,J. Biol. Chem., 1998, 273:11930-11936.
DW Green et al., American College of Surgeons, “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,” Jul. 2000, 191:93-105.
K-Y Jen et al., Stem Cells, “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” 2000, 18:307-319.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
New England BioLabs, Inc. Catalogue (1998): 121, 284.
Reynolds et al., Rational siRNA design for RNA interference, Mar. 2004, Nature Biotechnology, vol. 22, pp. 326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Watt Andrew T.
Zhang Hong
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals, Inc.-Patent Dept.
Knobbe Martens Olson & Bear LLP
Zara Jane
LandOfFree
Antisense modulation of BCL2-associated X protein expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of BCL2-associated X protein expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of BCL2-associated X protein expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185605